113 related articles for article (PubMed ID: 16931913)
1. Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer.
Hou P; Xing M
Cell Cycle; 2006 Sep; 5(17):2036-9. PubMed ID: 16931913
[No Abstract] [Full Text] [Related]
2. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer.
Richards ML
Surg Oncol Clin N Am; 2009 Jan; 18(1):39-52, viii. PubMed ID: 19056041
[TBL] [Abstract][Full Text] [Related]
3. Loss of p27 expression through RAS-->BRAF-->MAP kinase-dependent pathway in human thyroid carcinomas.
Motti ML; De Marco C; Califano D; De Gisi S; Malanga D; Troncone G; Persico A; Losito S; Fabiani F; Santoro M; Chiappetta G; Fusco A; Viglietto G
Cell Cycle; 2007 Nov; 6(22):2817-25. PubMed ID: 18032931
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
5. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
[TBL] [Abstract][Full Text] [Related]
6. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET.
Kasprzak L; Nolet S; Gaboury L; Pavia C; Villabona C; Rivera-Fillat F; Oriola J; Foulkes WD
J Med Genet; 2001 Nov; 38(11):784-7. PubMed ID: 11732489
[No Abstract] [Full Text] [Related]
7. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
[TBL] [Abstract][Full Text] [Related]
8. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
9. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
[TBL] [Abstract][Full Text] [Related]
10. BRAF and MEK mutations make a late entrance.
Duesbery N; Vande Woude G
Sci STKE; 2006 Mar; 2006(328):pe15. PubMed ID: 16569817
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
12. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
[TBL] [Abstract][Full Text] [Related]
13. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
14. Germline polymorphisms on RET proto-oncogene involved in medullary thyroid carcinoma in a Druze family.
Azzam N; Bar-Shalom R; Saab A; Fares F
Eur J Cancer; 2017 Sep; 82():149-152. PubMed ID: 28688347
[No Abstract] [Full Text] [Related]
15. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.
Tidyman WE; Rauen KA
Methods Mol Biol; 2010; 661():433-47. PubMed ID: 20812000
[TBL] [Abstract][Full Text] [Related]
16. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
17. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
18. Roles of RAS and BRAF mutations in thyroid carcinogenesis.
Fukushima T; Takenoshita S
Fukushima J Med Sci; 2005 Dec; 51(2):67-75. PubMed ID: 16555627
[TBL] [Abstract][Full Text] [Related]
19. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]